Vertex Pharmaceuticals Inc (VRTX)

VRTX (NASDAQ:Drugs) EQUITY
$120.18
neg -0.16
-0.13%
Today's Range: 119.52 - 122.14 | VRTX Avg Daily Volume: 1,691,400
Last Update: 03/30/15 - 12:21 PM EDT
Volume: 592,105
YTD Performance: 1.30%
Open: $121.23
Previous Close: $120.34
52 Week Range: $59.79 - $136.33
Oustanding Shares: 242,088,884
Market Cap: 28,469,652,758
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 8 9 8
Moderate Buy 1 1 1 1
Hold 10 9 7 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.05 2.06 1.88 1.79
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -37.45
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
-37.45 0.00 27.26
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.63% 70.02% 193.87%
GROWTH 12 Mo 3 Yr CAGR
Revenue -52.10 -0.59 -0.25
Net Income 0.00 -19.01 0.00
EPS 0.00 -23.43 0.00
Earnings for VRTX:
EBITDA -0.64B
Revenue 0.58B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $-0.82 $-0.86 $-1.72 $3.82
Number of Analysts 6 6 11 11
High Estimate $-0.74 $-0.75 $-0.48 $7.38
Low Estimate $-0.93 $-0.94 $-3.10 $0.77
Prior Year $-0.85 $-0.79 $-2.93 $-1.72
Growth Rate (Year over Year) 3.73% -8.65% 41.27% 322.13%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Here are healthcare stocks of all shares and sizes with strong charts.
Bullish
Oct 13, 2014 | 7:55 AM EDT
VRTX was upgraded from Neutral to Overweight, Piper Jaffray said. $125 price target. Expect combination approvals in 2015.

Look Past the Indecision Real Money Pro($)

We got the rally we were looking for -- so now what?
Watch the momentum names, which were the biggest positive today.
Bullish
Sep 05, 2014 | 7:42 AM EDT
VRTX was upgraded from Neutral to Buy, Goldman Sachs said. Company is cornering the cystic fybrosis market. $131 price target. 
Here are several themes that are still working -- and now you can get in at a bargain.
Bullish
Jun 25, 2014 | 7:41 AM EDT
VRTX raised its number, UBS said. Drivers of upside include price, heterozygotes, and takeout potential. $115 price target and Buy rati...
Bearish
Jun 25, 2014 | 7:33 AM EDT
VRTX was downgraded from Buy to Neutral, HC Wainwright said. $85 price target. 809 drug still has scientific risks.   

A Few Off-the-Table Trades Real Money Pro($)

You can always buy these names back.

Biotechs Flash the Green Light Real Money Pro($)

After a decline, the sector has built a base, and these names are breaking out.

Columnist Conversations

Market having a nice day to begin the week as increased merger activity, especially in the biotech/healthcare ...
I took a small SPY short at $207.90 on the ramp. Back small net short now. Banks doing terrific, across the bo...
DOW
The Dow sellers are RELENTLESSS. It is amazing..
Following a brief spike on Thursday afternoon, markets did calm down after Yellen gave some dovish remarks. T...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.